ARTICLE | Clinical News
Kisplyx lenvatinib mesylate regulatory update
September 26, 2016 7:00 AM UTC
The European Commission approved Kisplyx lenvatinib mesylate from Eisai to treat advanced or metastatic renal cell carcinoma (RCC) in combination with Afinitor everolimus in patients who have been tr...